CA2074839A1 - Modified factor vii anticoagulant proteins - Google Patents

Modified factor vii anticoagulant proteins

Info

Publication number
CA2074839A1
CA2074839A1 CA2074839A CA2074839A CA2074839A1 CA 2074839 A1 CA2074839 A1 CA 2074839A1 CA 2074839 A CA2074839 A CA 2074839A CA 2074839 A CA2074839 A CA 2074839A CA 2074839 A1 CA2074839 A1 CA 2074839A1
Authority
CA
Canada
Prior art keywords
factor vii
modified
modified factor
anticoagulant
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2074839A
Other languages
French (fr)
Other versions
CA2074839C (en
Inventor
Kathleen L. Berkner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2074839A1 publication Critical patent/CA2074839A1/en
Application granted granted Critical
Publication of CA2074839C publication Critical patent/CA2074839C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Factor VII of the coagulation cascade is modified to act as an anticoagulant.
Amino acid modifications are employed to produce a modified Factor VII having a substantially reduced susceptibility to activation by enzymes which typically activate wild-type Factor VII. The modified Factor VII is able to compete with wild-type Factor VII and/or VIIa for binding tissue factor, inhibiting clotting activity. As the modified Factor VII acts specifically to interrupt the coagulation cascade, pharmaceutical compositions of modified Factor VII may be administered in place of, or in conjunction with lower doses of, conventional anticoagulant therapies.
CA002074839A 1990-01-29 1991-01-25 Modified factor vii anticoagulant proteins Expired - Fee Related CA2074839C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47131390A 1990-01-29 1990-01-29
US471,313 1990-01-29
PCT/US1991/000552 WO1991011514A1 (en) 1990-01-29 1991-01-25 Anticoagulant proteins

Publications (2)

Publication Number Publication Date
CA2074839A1 true CA2074839A1 (en) 1991-07-30
CA2074839C CA2074839C (en) 2000-11-14

Family

ID=23871126

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002074839A Expired - Fee Related CA2074839C (en) 1990-01-29 1991-01-25 Modified factor vii anticoagulant proteins

Country Status (8)

Country Link
US (2) US5288629A (en)
EP (1) EP0521873B1 (en)
JP (2) JP3330932B2 (en)
AT (1) ATE180834T1 (en)
AU (1) AU651573B2 (en)
CA (1) CA2074839C (en)
DE (1) DE69131292T2 (en)
WO (1) WO1991011514A1 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US6475781B1 (en) 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
JPH05506361A (en) * 1990-05-17 1993-09-22 ダナ―ファーバー　キャンサー　インスティテュート　インク Trans-dominant suppressor gene for multimeric proteins
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
WO1992015686A1 (en) * 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
JPH08510746A (en) * 1993-05-21 1996-11-12 ザイモジェネティクス，インコーポレイティド Improved type VII factor
AU7050994A (en) * 1993-06-01 1994-12-20 Scripps Research Institute, The Human mutant tissue factor compositions useful as tissue factor antagonists
US5962418A (en) * 1993-06-18 1999-10-05 Nycomed Imaging A/S Factor VII-derived peptides
US5510248A (en) * 1993-06-22 1996-04-23 The University Of British Columbia Stable recombinant meizothrombin-like polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AR017831A1 (en) * 1997-12-10 2001-10-24 Pioneer Hi Bred Int METHOD FOR ALTERING THE COMPOSITION OF AMINO ACIDS OF A NATIVE PROTEIN OF INTEREST, PREPARED PROTEIN, AND POLINUCLEOTIDE
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
CA2373735A1 (en) 1999-07-02 2001-01-11 Genentech, Inc. Fviia antagonists
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
DK1257295T3 (en) 2000-02-11 2009-08-10 Bayer Healthcare Llc Factor VII or VIIA-like molecules
US20040102388A1 (en) * 2000-03-22 2004-05-27 High Katherine A. Modified blood clotting factors and methods of use
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) * 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
AU8755001A (en) 2000-09-13 2002-03-26 Novo Nordisk As Human coagulation factor vii variants
RU2326126C2 (en) 2000-09-13 2008-06-10 Ново Нордиск Хелт Кэр Аг Polypeptyde of hemostasis factor vii, production and application
WO2002055110A2 (en) * 2000-10-25 2002-07-18 Genzyme Corp Methods for treating blood coagulation disorders
AU2002218029A1 (en) * 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
CA2441580A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
WO2003027147A2 (en) 2001-09-27 2003-04-03 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US6960657B2 (en) * 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
JP2005530683A (en) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Liquid composition of factor VII polypeptide
KR20040065278A (en) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 Liquid composition of modified factor vii polypeptides
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
DK1499719T3 (en) * 2002-04-30 2011-02-28 Bayer Healthcare Llc Factor VII or VIIa polypeptide variants
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
PT1517698E (en) * 2002-06-21 2014-11-19 Novo Nordisk Healthcare Ag Stabilised solid compositions of factor viia polypeptides
DE60336555D1 (en) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag PEGYLATED GLYCO FORMS OF FACTOR VII
US6911323B2 (en) * 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
AU2003266931B2 (en) * 2002-09-30 2010-01-21 Bayer Healthcare Llc FVII or FVIIa variants having increased clotting activity
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
EP3103869A1 (en) 2003-03-18 2016-12-14 Novo Nordisk Health Care AG Method for the production of factor vii polypeptides
EP1605968A2 (en) * 2003-03-18 2005-12-21 Novo Nordisk Health Care AG Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
JP4847856B2 (en) 2003-03-20 2011-12-28 バイエル ヘルスケア エルエルシー Variants of FVII and FVIIa
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
BRPI0409936A (en) * 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag use of material, at least partially filled container, and medical kit
RU2373282C2 (en) 2003-06-19 2009-11-20 Байер Хелткэр Ллк VERSIONS OF GLA DOMAIN OF FACTOR VII OR VIIa
ES2335994T3 (en) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag PHARMACEUTICAL, LIQUID, WATERPROOF POLYPEPTIDE COMPOSITION FACTOR VII.
BRPI0413518A (en) 2003-08-14 2006-10-10 Novo Nordisk Healthcare Ag aqueous liquid pharmaceutical composition, method for preparing and using same, method for treating a factor responsive syndrome vii, and, airtight container
CN1863908B (en) * 2003-09-09 2010-08-04 诺和诺德医疗保健公司 Coagulation factor vii polypeptides
EP1684790A4 (en) * 2003-11-18 2008-04-30 Iconic Therapeutics Inc Homogeneous preparations of chimeric proteins
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
SI2298287T1 (en) * 2003-12-19 2018-08-31 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
WO2005075635A2 (en) * 2004-02-03 2005-08-18 Novo Nordisk Health Care Ag Coagulation factor vii/viia variants lacking a functional lipid membrane binding domain
JP5216580B2 (en) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス Glycopegylated factor IX
EP1926817A2 (en) 2005-09-14 2008-06-04 Novo Nordisk Health Care AG Human coagulation factor vii polypeptides
WO2007039475A1 (en) * 2005-09-21 2007-04-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
ES2399138T3 (en) * 2006-03-16 2013-03-26 Stellaris Pharmaceuticals Aps Local treatment with factor VII
JP2009543841A (en) * 2006-07-17 2009-12-10 ノボ ノルディスク ヘルス ケア アーゲー Novel uses of factor VIIA analogs with increased activity
RU2571931C2 (en) * 2007-04-13 2015-12-27 Каталист Биосайенсис, Инк. Modified factor vii-based polypeptides and thereof application
JP5876649B2 (en) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ Improved process for producing nucleotide sugars
TWI465247B (en) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc Factor vii polypeptides that are modified and uses thereof
RS56496B1 (en) 2009-06-09 2018-01-31 Prolong Pharmaceuticals Llc Hemoglobin compositions
TWI595004B (en) 2010-11-03 2017-08-11 介控生化科技公司 Modified factor ix polypeptides and uses thereof
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
ATE74164T1 (en) * 1985-04-22 1992-04-15 Genetics Inst MANUFACTURING WITH HIGH PERFORMANCE OF ACTIVE FACTOR IX.
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (en) * 1987-06-25 1987-06-25 Novo Industri As PROTEIN
EP0296413A2 (en) * 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrid protein C and method for its preparation
US4994371A (en) * 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors

Also Published As

Publication number Publication date
ATE180834T1 (en) 1999-06-15
CA2074839C (en) 2000-11-14
EP0521873A4 (en) 1993-05-05
DE69131292T2 (en) 1999-09-30
US5824639A (en) 1998-10-20
EP0521873A1 (en) 1993-01-13
AU651573B2 (en) 1994-07-28
JPH05500161A (en) 1993-01-21
EP0521873B1 (en) 1999-06-02
JP2002247996A (en) 2002-09-03
WO1991011514A1 (en) 1991-08-08
AU7300291A (en) 1991-08-21
US5288629A (en) 1994-02-22
JP3330932B2 (en) 2002-10-07
DE69131292D1 (en) 1999-07-08

Similar Documents

Publication Publication Date Title
CA2074839A1 (en) Modified factor vii anticoagulant proteins
AU563925B2 (en) Removal of lipid containing virus in blood
CA1244763A (en) Blood coagulation inhibiting proteins, processes for preparing them and their uses
AU607303B2 (en) Composition of anticoagulants
Elg et al. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits
CA2060507A1 (en) Factor xa based anticoagulant compositions
EP0233013A3 (en) Modified enzyme
Janoff et al. Digestion of lung proteins by human leukocyte granules in vitro
AU657758B2 (en) A parenterally administrable drug having thrombolytic activity and containing protein C
US4287180A (en) Method for treating blood clotting factor inhibitors
US5922358A (en) Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications
CA2154080A1 (en) Novel anticoagulant cofactor activity
EP0225020A3 (en) Peptides comprising, in sequence, units selected from the amino-acid residues 17 to 24 of vip
US4357321A (en) Method and composition for treating clotting factor inhibitors
US4286056A (en) Method for making therapeutic enzyme compositions
CA2175061A1 (en) Muteins of Beta-Galactosidase Fragments Having Increased Activity
JPS57134419A (en) Stable anticoagulant of blood
US4459288A (en) Therapeutic blood clotting factor compositions and their use
AU7670687A (en) Improvements in or relating to the treatment of occlusive vascular diseases
Burns et al. Observations on vitamin C activity of D-ascorbic acid.
Iwata et al. Existence of two kinds of thiol protease inhibitors in rat serum
US4663164A (en) Aqueous compositions for treating blood clotting factor inhibitors
JPS5598196A (en) Fractionation of fibrinogen or its constituents and their use
EP1181046B1 (en) 10-formyltetrahydrofolate dehydrogenase as therapeutical agent
CA2075901A1 (en) Tissue plasminogen activator having fibrin specific properties

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed